From “negative” trial to positive clinical impact: mitigating eligibility criteria–induced temporal selection bias in emulated clinical trials

Abstract While randomized controlled trials (RCTs) guide clinical practice, their completion may also influence real-world treatment patterns. We investigated whether the outcomes of trial emulation differ before and after the publication of the WARCEF (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction) randomized controlled trial. We emulated the WARCEF trial using EHR data from the Mayo Clinic Platform, comparing Warfarin and Aspirin in patients with heart failure and reduced ejection fraction (HFrEF). Analyses were stratified by the WARCEF completion date (July 2014), using intention-to-treat (ITT) frameworks. For the ITT analysis, the cohort size before 2014 consisted of 37,225 patients on Aspirin and 2022 on Warfarin, while after 2014, the cohort included 26,192 patients on Aspirin and 1080 on Warfarin. No significant treatment difference was observed before July 2014, 1.025 (95% CI: 0.6144 – 1.709, p = 0.9255), consistent with the findings of the WARCEF trial. However, after trial completion, Warfarin was associated with increased risk, 2.181 (95% CI: 1.676 – 2.839, p < 0.001). These findings initially suggested that the completion of the WARCEF trial and subsequent guideline updates were associated with changes in observed treatment effects in real-world emulation. However, further analyses indicate that the observed differences are primarily driven by the application of specific eligibility criteria rather than the trial completion date itself. In particular, the inclusion of restrictive eligibility criteria alters cohort composition and event timing, introducing selection bias that materially affects treatment effect estimates. This highlights that, in trial emulation studies, eligibility criteria can have a greater impact on observed outcomes than temporal stratification alone. Accurate emulation therefore requires careful alignment of eligibility definitions with the original trial design, as inappropriate or overly restrictive criteria may induce selection bias and distort causal inference, independent of trial publication timing.

Authors

Institutions

Publication Details

Journal
npj Health Systems
Published
2026-05-27
DOI
https://doi.org/10.1038/s44401-026-00082-3
Primary Topic
Advanced Causal Inference Techniques
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

From “negative” trial to positive clinical impact: mitigating eligibility criteria–induced temporal selection bias in emulated clinical trials

Nansu Zong, Jingna Feng, Pengyang Li, Sivaraman Rajaganapathy et al.
npj Health Systems
Advanced Causal Inference Techniques
article

From “negative” trial to positive clinical impact: mitigating eligibility criteria–induced temporal selection bias in emulated clinical trials

Nansu Zong, Jingna Feng, Pengyang Li, Sivaraman Rajaganapathy, Jose James, Soulmaz Boroumand, Xiaodi Li, M E Lee, Phil Fiero, Cui Tao, Xinyue Hu, Jun Chen, Xiaoke Liu, Richard Larsen, Jianfu Li, Yue Yu
article en

Abstract

Abstract While randomized controlled trials (RCTs) guide clinical practice, their completion may also influence real-world treatment patterns. We investigated whether the outcomes of trial emulation differ before and after the publication of the WARCEF (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction) randomized controlled trial. We emulated the WARCEF trial using EHR data from the Mayo Clinic Platform, comparing Warfarin and Aspirin in patients with heart failure and reduced ejection fraction (HFrEF). Analyses were stratified by the WARCEF completion date (July 2014), using intention-to-treat (ITT) frameworks. For the ITT analysis, the cohort size before 2014 consisted of 37,225 patients on Aspirin and 2022 on Warfarin, while after 2014, the cohort included 26,192 patients on Aspirin and 1080 on Warfarin. No significant treatment difference was observed before July 2014, 1.025 (95% CI: 0.6144 – 1.709, p = 0.9255), consistent with the findings of the WARCEF trial. However, after trial completion, Warfarin was associated with increased risk, 2.181 (95% CI: 1.676 – 2.839, p < 0.001). These findings initially suggested that the completion of the WARCEF trial and subsequent guideline updates were associated with changes in observed treatment effects in real-world emulation. However, further analyses indicate that the observed differences are primarily driven by the application of specific eligibility criteria rather than the trial completion date itself. In particular, the inclusion of restrictive eligibility criteria alters cohort composition and event timing, introducing selection bias that materially affects treatment effect estimates. This highlights that, in trial emulation studies, eligibility criteria can have a greater impact on observed outcomes than temporal stratification alone. Accurate emulation therefore requires careful alignment of eligibility definitions with the original trial design, as inappropriate or overly restrictive criteria may induce selection bias and distort causal inference, independent of trial publication timing.

npj Health SystemsVol. 3(1)
Mayo Clinic (US), Virginia Commonwealth University (US), Mayo Clinic in Arizona (US), St. Luke's Hospital (US), Mayo Clinic in Florida (US)
National Institutes of Health, National Institute of General Medical Sciences
Reduced inequalities
Openalex Percentile: Top 5%
Advanced Causal Inference Techniques
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.